Kleber Yotsumoto Fertrin

List of Publications by Year
in descending order

75 papers	884 citations	516561 16 h-index	501076 28 g-index
76 all docs	76 docs citations	76 times ranked	1567 citing authors

#	Article	IF	Citations
1	Main Complications during Pregnancy and Recommendations for Adequate Antenatal Care in Sickle Cell Disease: A Literature Review. Revista Brasileira De Ginecologia E Obstetricia, 2022, 44, 593-601.	0.3	3
2	Iron overload disorders. Hepatology Communications, 2022, 6, 1842-1854.	2.0	33
3	Benserazide as a potential novel fetal hemoglobin inducer: an observational study in non-carriers of hemoglobin disorders. Blood Cells, Molecules, and Diseases, 2021, 87, 102511.	0.6	9
4	Screening for myeloid mutations in patients with myelodysplastic syndromes and AML with myelodysplasia-related changes. Hematology, Transfusion and Cell Therapy, 2021, , .	0.1	0
5	Neurocognitive Assessment of Adults with Sickle Cell Disease: A Descriptive Study. Blood, 2021, 138, 4172-4172.	0.6	1
6	Crizanlizumab-Associated Painful Febrile Reaction in Sickle Cell Disease Patients. Blood, 2021, 138, 4186-4186.	0.6	3
7	Monocytes from Patients with Polycythemia Vera Express Molecules Related to Stress Erythropoiesis and Have Increased Erythrocyte Phagocytosis. Blood, 2021, 138, 1466-1466.	0.6	1
8	Crizanlizumab Therapy Is Associated with Lower Levels of Circulating Extracellular Vesicles in Sickle Cell Disease Patients. Blood, 2021, 138, 955-955.	0.6	0
9	Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1181-1201.	2.3	43
10	Blood use and transfusion needs at a large health care system in Washington state during the SARSâ€CoV â€2 pandemic. Transfusion, 2020, 60, 2859-2866.	0.8	15
11	Genetic and Clinical Heterogeneity in Thirteen New Cases with Aceruloplasminemia. Atypical Anemia as a Clue for an Early Diagnosis. International Journal of Molecular Sciences, 2020, 21, 2374.	1.8	25
12	Red blood cells microparticles are associated with hemolysis markers and may contribute to clinical events among sickle cell disease patients. Annals of Hematology, 2019, 98, 2507-2521.	0.8	29
13	High erythropoietin may be associated with vascular complications in patients with secondary erythrocytosis caused by high oxygen affinity variant hemoglobin Coimbra. Blood Cells, Molecules, and Diseases, 2019, 79, 102353.	0.6	2
14	Myocardial Iron Overload in Sickle Cell Disease: A Rare But Potentially Fatal Complication of Transfusion. Transfusion Medicine Reviews, 2019, 33, 170-175.	0.9	5
15	Hypocholesterolemia and dysregulated production of angiopoietin-like proteins in sickle cell anemia patients. Cytokine, 2019, 120, 88-91.	1.4	4
16	Clinical relevance of heterozygosis for aceruloplasminemia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 266-271.	1.1	12
17	Different morphological and gene expression profile in placentas of the same sickle cell anemia patient in pregnancies of opposite outcomes. Experimental Biology and Medicine, 2019, 244, 395-403.	1.1	0
18	Abnormal Cytokine Production By Mast Cell Cultures from Sickle Cell Anemia Patients in Response to Inflammatory Stimuli and to Co-Culture with Eosinophils. Blood, 2019, 134, 3566-3566.	0.6	0

#	Article	IF	Citations
19	Safe Use of Hydroxyurea in Sickle Cell Disease Patients Hospitalized for Painful Vaso-Occlusive Episodes: Results of the Randomized, Open-Label Helps Study. Blood, 2019, 134, 2303-2303.	0.6	1
20	A thalidomideâ€“hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes. Experimental Hematology, 2018, 58, 35-38.	0.2	9
21	It is never too late to rethink serum folate. Hematology, Transfusion and Cell Therapy, 2018, 40, 295-297.	0.1	0
22	Differences in heme and hemopexin content in lipoproteins from patients with sickle cell disease. Journal of Clinical Lipidology, 2018, 12, 1532-1538.	0.6	14
23	Impairment of Nitric Oxide Pathway by Intravascular Hemolysis Plays a Major Role in Mice Esophageal Hypercontractility: Reversion by Soluble Guanylyl Cyclase Stimulator. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 194-202.	1.3	3
24	Benserazide As a Novel Fetal Hemoglobin Inducer: An Observational Study in Non-Carriers of Hemoglobin Disorders. Blood, 2018, 132, 2345-2345.	0.6	1
25	Aceruloplasminemia and Paroxysmal Nocturnal Hemoglobinuria Uncover Differential Expressions of Ceruloplasmin and Ferroportin in Immune Cells. Blood, 2018, 132, 4895-4895.	0.6	0
26	Elevated Levels of Hepatokine Angiopoietin-like 3 Correlate Paradoxically with Hypocholesterolemia and Hemolysis in Sickle Cell Anemia. Blood, 2018, 132, 1069-1069.	0.6	0
27	Crosstalk between Mast Cells and Eosinophils Can Contribute to Pathophysiology of Sickle Cell Anemia. Blood, 2018, 132, 1070-1070.	0.6	2
28	Serum Metabolic Alterations upon Zika Infection. Frontiers in Microbiology, 2017, 8, 1954.	1.5	36
29	Rock Inhibitor Fasudil Reduces Leukocyte-Endothelium Interactions in the Microvasculature of a Sickle Cell Mouse Model of Allergic Inflammation. Blood, 2017, 130, 961-961.	0.6	0
30	Reduced rate of sickleâ€related complications in Brazilian patients carrying HbFâ€promoting alleles at the BCL11A and HMIPâ€2 loci. British Journal of Haematology, 2016, 173, 456-460.	1.2	25
31	A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. Blood, 2016, 128, 1555-1561.	0.6	47
32	Abnormal expression of inflammatory genes in placentas of women with sickle cell anemia and sickle hemoglobin C disease. Annals of Hematology, 2016, 95, 1859-1867.	0.8	12
33	Sickle Cell Imaging Flow Cytometry Assay (SIFCA). Methods in Molecular Biology, 2016, 1389, 279-292.	0.4	11
34	Priapism in Sickle Cell Disease: New Aspects of Pathophysiology. , 2016, , 269-283.		0
35	Modulation of Hemolytic and Hemoglobin/Heme Scavenging Profiles in Sickle Cell Anemia, Hereditary Spherocytosis and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2016, 128, 1257-1257.	0.6	0
36	Increased circulating PEDF and low sICAM-1 are associated with sickle cell retinopathy. Blood Cells, Molecules, and Diseases, 2015, 54, 33-37.	0.6	15

#	Article	IF	Citations
37	Differential Diagnosis of Hereditary and Acquired Thrombocytopenia By the Immature Platelet Fraction and Thrombopoietin Levels. Blood, 2015, 126, 1049-1049.	0.6	2
38	Urinary Bladder Dysfunction in Transgenic Sickle Cell Disease Mice. PLoS ONE, 2015, 10, e0133996.	1.1	12
39	Association of Nitric Oxide Synthase and Matrix Metalloprotease Single Nucleotide Polymorphisms with Preeclampsia and Its Complications. PLoS ONE, 2015, 10, e0136693.	1.1	20
40	Circulating Lipoprotein Concentrations Correlate with Total but Not Free Heme in Different Sickle Cell Disease Genotypes. Blood, 2015, 126, 4580-4580.	0.6	0
41	Hypersegmented Neutrophil Percentage Using Automated Digital Cell Morphology: A Simple Laboratory Parameter to Monitor Hydroxyurea Therapy in Sickle Cell Disease Patients. Blood, 2015, 126, 2188-2188.	0.6	0
42	Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients. British Journal of Haematology, 2014, 164, 286-295.	1.2	15
43	Pregnancy in sickle cell disease â€“ do we know what to expect?. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 313-314.	0.7	0
44	Imaging flow cytometry for automated detection of hypoxiaâ€induced erythrocyte shape change in sickle cell disease. American Journal of Hematology, 2014, 89, 598-603.	2.0	60
45	Erythropoiesisâ€driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15. American Journal of Hematology, 2014, 89, 385-390.	2.0	25
46	Influence of the Î²s haplotype and Î±-thalassemia on stroke development in a Brazilian population with sickle cell anaemia. Annals of Hematology, 2014, 93, 1123-1129.	0.8	28
47	Imaging flow cytometry documents incomplete resistance of human sickle F-cells to ex vivo hypoxia-induced sickling. Blood, 2014, 124, 658-660.	0.6	6
48	High Transferrin Saturation Is Associated with Lower Monocytic Ferritin Heavy Chain Expression in Sickle Cell Anemia Patients. Blood, 2014, 124, 4058-4058.	0.6	1
49	Hyperexpression of Inflammatory Genes in Placental Tissue in Patients with Hemoglobin SC Disease. Blood, 2014, 124, 1369-1369.	0.6	0
50	Differential Expression of microRNAs and Transcription Factors in Primary Human Erythroblast Culture of Î²-Thalassemia Intermedia Patients. Blood, 2014, 124, 2691-2691.	0.6	0
51	Association of MBL2 polymorphism with Leg Ulcers Development in Sickle Cell Anemia Patients. Blood, 2014, 124, 4912-4912.	0.6	0
52	Amlodipine Reduces Cardiac Iron Overload in Patients with Thalassemia Major: A Pilot Trial. American Journal of Medicine, 2013, 126, 834-837.	0.6	51
53	Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clinical Microbiology and Infection, 2013, 19, 745-751.	2.8	118
54	Brazilian Association of Thalassemia protocol for iron chelation therapy in patients under regular transfusion. Revista Brasileira De Hematologia E Hemoterapia, 2013, 35, 428-34.	0.7	17

#	Article	IF	Citations
55	Inhibition Of the Rho/Rho-Kinase Pathway Reduces In Vitro Adhesion Of Sickle Cell Anemia Eosinophils To Human Endothelial Cells. Blood, 2013, 122, 2219-2219.	0.6	1
56	Imaging Flow Cytometry Documents Incomplete Resistance Of F-Cells To Hypoxia-Induced Sickling In Blood Samples From Patients With Sickle Cell Anemia. Blood, 2013, 122, 183-183.	0.6	0
57	Sickling Cells, Cyclic Nucleotides, and Protein Kinases: The Pathophysiology of Urogenital Disorders in Sickle Cell Anemia. Anemia, 2012, 2012, 1-13.	0.5	12
58	Left and right ventricular function and volume assessment in young thalassemia major patients with no related myocardial iron overload. Annals of Hematology, 2012, 91, 1839-1844.	0.8	7
59	JAK2 V617FMutation Prevalence in Myeloproliferative Neoplasms in Pernambuco, Brazil. Genetic Testing and Molecular Biomarkers, 2012, 16, 802-805.	0.3	9
60	Thalassemia major phenotypes secondary to the association of Î² 5â€²<scp>UTR</scp> +20(<scp>C</scp>â†’<scp>T</scp>) allele with Î² 39(<scp>C</scp>â†’<scp>T</scp>). European Journal of Haematology, 2012, 89, 273-275.	1.1	1
61	Monocyte Shift to a Non-Classical CD14dim/CD16+ Phenotype Correlates with Fetal Hemoglobin Levels in Sickle Cell Anemia Patients Treated with Hydroxyurea. Blood, 2012, 120, 817-817.	0.6	1
62	European Chromosome 6 Haplotypes Significantly Augment Fetal Hemoglobin Levels in Brazilian Sickle Cell Anemia Patients: Influence of Four HBS1L-MYB Intergenic Region SNPs. Blood, 2012, 120, 1002-1002.	0.6	0
63	Hepcidin Production in Ineffective Erythropoiesis and Chronic Hemolysis: Insights on the Crosstalk Between Erythropoiesis and Iron Metabolism. Blood, 2011, 118, 346-346.	0.6	1
64	EYA3 May Be Required for Globin Gene Expression in Erythroid Differentiation. Blood, 2011, 118, 4797-4797.	0.6	0
65	Increased Angiogenic Activity of Plasma From Sickle Cell Disease Patients and Anti-Angiogenic Effects of Hydroxyurea: Evaluation of Capillary-Like Structure Formation of Human Umbilical Vein Endothelial Cells on Matrigel. Blood, 2011, 118, 899-899.	0.6	3
66	Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment. Expert Review of Hematology, 2010, 3, 443-458.	1.0	73
67	Altered Functional Properties of Eosinophils In Sickle Cell Anemia and Effects of Hydroxyurea Therapy. Blood, 2010, 116, 2656-2656.	0.6	10
68	Hydroxyurea Induces Hepcidin Expression In Monocytes In Sickle Cell Anemia Patients. Blood, 2010, 116, 2653-2653.	0.6	0
69	Hb H disease resulting from the association of an Î±Â°-thalassemia allele [-(Î±)20.5] with an unstable Î±-globin variant [Hb Icaria]: first report on the occurrence in Brazil. Genetics and Molecular Biology, 2009, 32, 712-715.	0.6	3
70	Upregulation of the Anti-Apoptotic Protein, Survivin, in Hematopoietic Cells in Sickle Cell Anemia and Effects of Hydroxyurea Therapy.. Blood, 2009, 114, 1532-1532.	0.6	0
71	Reduction of Urinary Bladder Activity in Transgenic Sickle Cell Disease Mice.. Blood, 2009, 114, 2580-2580.	0.6	0
72	Effect of High Levels of Growth Differentiation Factor 15 (GDF15) On Hepcidin Expression in Monocytes of Î²-Thalassemia Intermedia Patients.. Blood, 2009, 114, 4061-4061.	0.6	0

#	Article	IF	Citations
73	Inflammatory Mediators Are Increased in Leukocytes of IVS-I-6 (Tâ†'C) Homozygous Î²-Thalassemia Intermedia.. Blood, 2009, 114, 4068-4068.	0.6	0
74	UDP-glucuronosyltransferase 1 gene promoter polymorphism is associated with increased serum bilirubin levels and cholecystectomy in patients with sickle cell anemia. Clinical Genetics, 2003, 64, 160-162.	1.0	45
75	Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vasoâ€occlusive episodes during the randomized, openâ€label <scp>HELPS</scp> study. British Journal of Haematology, 0, , .	1.2	2